



09/284,424



RN 177742-23-3 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-2-oxo-3-[[[6-oxo-5-
[[[(phenylmethoxy)carbonyl]amino]-2-(2-thienyl)-1(6H)-
pyrimidinyl]acetyl]amino]butyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 177742-24-4 CAPLUS


CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-5-
[[[(phenylmethyl)amino]carbonyl]amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-
oxobutyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177742-25-5 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[5-[[[2,5-dihydro-2-furanyl]carbonyl]amino]-2-(4-fluorophenyl)-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 177742-26-6 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[5-[[[6-(dimethylamino)-1-oxohexyl]amino]-2-(4-fluorophenyl)-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 177742-27-7 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-5-[(phenylsulfonyl)amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 177742-28-8 CAPLUS


CN Benzoic acid, 2,4-dichloro-, 3-[[[5-amino-2-(4-fluorophenyl)-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-4-carboxy-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 22 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1996:317557 CAPLUS
 DOCUMENT NUMBER: 125:48676
 TITLE: Interleukin-1.β. converting enzyme inhibition
 blocks progression of type II collagen-induced
 arthritis in mice
 AUTHOR(S): Ku, George; Faust, Ted; Lauffer, Linda L.;
 Livingston, David J.; Harding, Matthew W.
 CORPORATE SOURCE: Vertex Pharmaceuticals Incorporated, Cambridge, MA,
 01239, USA
 SOURCE: Cytokine (1996), 8(5), 377-386
 CODEN: CYTIE9; ISSN: 1043-4666
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 151594-01-3, VE 16084
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (interleukin-1.β. converting enzyme inhibitors VE-13045 and
 VE-16084 block progression of type II collagen-induced arthritis in mice)
 RN 151594-01-3 CAPLUS
 CN L-Alaninamide,
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
 [(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 23 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1996:214750 CAPLUS
 DOCUMENT NUMBER: 124:290273
 TITLE: Preparation of peptide analogs as inhibitors of
 interleukin-1 beta converting enzyme (ICE)
 INVENTOR(S): Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David
 J.;
 Mullican, Michael D.; Murcko, Mark A.; Livingston,
 David J.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorp., USA
 SOURCE: PCT Int. Appl., 374 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535308	A1	19951228	WO 1995-US7617	19950616
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5756466	A	19980526	US 1994-261452	19940617
US 5656627	A	19970812	US 1995-405581	19950317
US 5847135	A	19981208	US 1995-440898	19950525
AU 9529446	A1	19960115	AU 1995-29446	19950616
EP 784628	A1	19970723	EP 1995-925257	19950616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9508051	A	19971021	BR 1995-8051	19950616
JP 10504285	T2	19980428	JP 1995-502478	19950616
NO 9605365	A	19970217	NO 1996-5365	19961213
FI 9605036	A	19970214	FI 1996-5036	19961216
PRIORITY APPLN. INFO.:				
			US 1994-261452	19940617
			US 1995-405581	19950317
			US 1995-440898	19950525
			WO 1995-US7617	19950616

09/284,424

OTHER SOURCE(S): MARPAT 124:290273

IT 175209-21-9P 175209-22-0P 175209-42-4P

175209-46-8P 175209-83-3P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide analogs as inhibitors of interleukin-1 beta converting enzyme for treating inflammatory, autoimmune and neurodegenerative diseases)

RN 175209-21-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[[[(phenylmethoxy)carbonyl]amino]-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-22-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 175209-42-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-2-[(1H-imidazol-2-ylcarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/284,424




RN 175209-46-8 CAPLUS
CN Benzoic acid, 2,6-dichloro-,
(3S)-4-carboxy-2-oxo-3-[[[(2S)-1-oxo-2-[2-oxo-
3-[(1-oxo-3-phenylpropyl)amino]-1(2H)-pyridinyl]propyl]amino]butyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-83-3 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[(3S)-2,3,4,5-
tetrahydro-2-oxo-5-(1-oxo-3-phenylpropyl)-3-[(1-oxo-3-phenylpropyl)amino]-
1H-1,5-benzodiazepin-1-yl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 24 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:996306 CAPLUS

DOCUMENT NUMBER: 124:146843

TITLE: Preparation of N-(pyrimidinyl)aspartic acid
 .alpha.-substituted Me ketones and aspartic acid
 aldehydes as interleukin-1.beta. protease inhibitors

INVENTOR(S): Dolle, Roland E.; Prouty, Catherine P.; Chaturvedula,
 Prasad V.; Schmidt, Stanley J.

PATENT ASSIGNEE(S): Sanofi Winthrop, Inc., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526958	A1	19951012	WO 1995-US3909	19950329
W: AU, CA, CN, FI, HU, JP, MX, NO, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2186511	AA	19951012	CA 1995-2186511	19950329
AU 9522323	A1	19951023	AU 1995-22323	19950329
AU 703451	B2	19990325		
EP 752987	A1	19970115	EP 1995-915448	19950329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1149292	A	19970507	CN 1995-193258	19950329
HU 75715	A2	19970528	HU 1996-2664	19950329
JP 09511249	T2	19971111	JP 1995-525821	19950329
NO 9604058	A	19960926	NO 1996-4058	19960926
FI 9603897	A	19960927	FI 1996-3897	19960927
PRIORITY APPLN. INFO.:			US 1994-221712	19940331
			WO 1995-US3909	19950329

OTHER SOURCE(S): MARPAT 124:146843

IT 173305-25-4P 173305-26-5P 173305-41-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-(pyrimidinyl)aspartic acid .alpha.-substituted Me ketones and aspartic acid aldehydes as interleukin-1.beta. protease inhibitors)

RN 173305-25-4 CAPLUS


CN Benzoic acid, 2,6-dichloro-,

(3S)-4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-

5-[[[phenylmethoxy]carbonyl]amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 173305-26-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[2-(4-fluorophenyl)-5-[[4-(methylthio)benzoyl]amino]-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173305-41-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[6-oxo-5-[[[phenylmethoxy]carbonyl]amino]-2-(2-thienyl)-1(6H)-pyrimidinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 25 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:874345 CAPLUS

DOCUMENT NUMBER: 124:56682

TITLE: Synthesis and evaluation of diacylhydrazines as inhibitors of the interleukin-1.β. converting enzyme (ICE)

AUTHOR(S): Graybill, Todd L.; Dolle, Roland E.; Helaszek, Carla T.; Ator, Mark A.; Strasters, Joost

CORPORATE SOURCE: Department Medicinal Chemistry, Biochemistry, Analytical Chemistry, Sterling Winthrop Pharmaceuticals Research Division, Collegeville, PA, 19426, USA

SOURCE: Bioorg. Med. Chem. Lett. (1995), 5(11), 1197-202
CODEN: BMCLE8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 151594-01-3

RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)


(prepn., hydrolytic stability, and interleukin-1.β. converting enzyme inhibitory activity of peptidyl diacylhydrazine inhibitors)

RN 151594-01-3 CAPLUS

CN L-Alaninamide,


N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 26 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1995:819770 CAPLUS
 DOCUMENT NUMBER: 123:225595
 TITLE: Secretion of human monocyte mature IL-1.β.:
 optimization of culture conditions and inhibition by
 ICE inhibitors
 AUTHOR(S): Uhl, J.; Krasney, P.; Brophy, L.; Arnold, R.; Dolle,
 R.; Helaszek, C.; Miller, R.; Gilman, S.; Ator, M.
 CORPORATE SOURCE: Dep. Inflammation, Collegeville, PA, 19426, USA
 SOURCE: Inflammation Res. (1995), 44(Suppl. 2), S211-S212
 CODEN: INREFB; ISSN: 1023-3830
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 151594-01-3 153088-74-5
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (interleukin-1.β. converting enzyme inhibitors suppress the
 secretion of mature interleukin-1.β. by human monocytes)
 RN 151594-01-3 CAPLUS
 CN L-Alaninamide,
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
 [(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153088-74-5 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-3-methyl-1-oxo-2-
 [[[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 27 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1995:735232 CAPLUS
 DOCUMENT NUMBER: 123:170185
 TITLE: Preparation of peptide analogs as irreversible
 interleukin-1.beta. protease inhibitors.
 INVENTOR(S): Dolle, Roland E.; Osifo, Irennegbe K.; Schmidt,
 Stanley J.; Hoyer, Denton W.; Ross, Tina M.;
 Chaturvedula, Prasad; Prouty, Catherine P.; Awad,
 Mohamed M.; Salvino, Joseph M.; et al.
 PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA
 SOURCE: Eur. Pat. Appl., 31 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 623592	A1	19941109	EP 1994-201161	19940427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2122227	AA	19941030	CA 1994-2122227	19940426
JP 07025865	A2	19950127	JP 1994-89532	19940427
AU 9460752	A1	19941103	AU 1994-60752	19940428
AU 676887	B2	19970327		
IL 109471	A1	19980222	IL 1994-109471	19940428
FI 9402005	A	19941030	FI 1994-2005	19940429
NO 9401580	A	19941031	NO 1994-1580	19940429
HU 68563	A2	19950628	HU 1994-1251	19940429
PRIORITY APPLN. INFO.:			US 1993-55051	19930429
OTHER SOURCE(S): MARPAT 123:170185				
IT 151594-01-3P 153088-74-5P 162852-51-9P				
162852-52-0P 162852-53-1P 162852-54-2P				
162852-55-3P 166388-79-0P 166388-80-3P				
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(prepn. of peptide ketone analogs as irreversible interleukin-1.beta. protease inhibitors)				
RN 151594-01-3 CAPLUS				
CN L-Alaninamide,				
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.

09/284,424




RN 153088-74-5 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-3-methyl-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162852-51-9 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[3-(1H-imidazol-4-yl)-2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162852-52-0 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[(methoxycarbonyl)amino]acetyl]

09/284,424

amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-53-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-54-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxo-3-(2-thienyl)propyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162852-55-3 CAPLUS

09/284,424

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166388-79-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxo-3-phenylpropyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166388-80-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-2-oxo-3-[[1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]butyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 28 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1995:686700 CAPLUS
 DOCUMENT NUMBER: 123:84008
 TITLE: Preparation of peptides inhibiting interleukin
 1.beta.
 INVENTOR(S): release useful as antiinflammatory agents.
 Heng, Richard; Leutwiler, Albert; Revesz, Laszlo;
 Wuethrich, Hans-Juerg
 PATENT ASSIGNEE(S): Sandoz Ltd., Switz.; Sandoz-Patent-GmbH;
 Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.
 SOURCE: Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 618223	A2	19941005	EP 1994-810137	19940303
EP 618223	A3	19960612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2117121	AA	19940909	CA 1994-2117121	19940307
JP 06340691	A2	19941213	JP 1994-35748	19940307
PRIORITY APPLN. INFO.:			GB 1993-4686	19930308
			GB 1993-5382	19930316
			GB 1993-5386	19930316
			GB 1993-8328	19930422
			GB 1993-8329	19930422
			GB 1993-8330	19930422

OTHER SOURCE(S): MARPAT 123:84008
 IT 165112-13-0P 165112-16-3P 165112-18-5P
 165112-26-5P 165112-28-7P 165112-30-1P
 165112-33-4P 165112-35-6P 165112-62-9P
 165112-85-6P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. of peptides inhibiting interleukin 1.beta. release useful as
 antiinflammatory agents)
 RN 165112-13-0 CAPLUS
 CN L-Alaninamide,
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-2-
 oxo-3-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)oxy]propyl]-, (R)- (9CI)
 (CA
 INDEX NAME)

Absolute stereochemistry.

The chemical structure shows a 12-membered cyclic peptide derivative. The backbone consists of a ring of six amide bonds. The side chains are: a phenyl group (Ph), an isopropyl group (i-Pr), a methyl group (Me), a carboxylic acid group (CO₂H), and a norbornene group (bicyclo[2.2.1]hept-5-en-2-yl). The stereochemistry is indicated by dashed and wedged bonds at the chiral centers.

RN 165112-16-3 CAPLUS
CN L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[3-[(9-acridinylcarbonyl)oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

[illegible]

CN L-Alaninamide,
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
 [(1H-indol-3-ylcarbonyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


CC1(C)NC(=O)SC1C(=O)N[C@@H](C(=O)O)C(=O)OCC(=O)OC(=O)c2c[nH]c3ccccc23

CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
[[2-methylimidazo[1,2-a]pyridin-3-yl)carbonyl]oxy]-2-oxopropyl)- (9CI)

09/284,424

(CA INDEX NAME)

Absolute stereochemistry.




RN 165112-28-7 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
[[(2-methoxy-3-methyl-4-quinolinyl)carbonyl]oxy]-2-oxopropyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 165112-30-1 CAPLUS


CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
[[(1,3-dimethyl-1H-indol-2-yl)carbonyl]oxy]-2-oxopropyl]- (9CI) (CA
INDEX
NAME)

Absolute stereochemistry.



09/284,424




RN 165112-33-4 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-2-oxo-3-[(9H-xanthen-9-ylcarbonyl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165112-35-6 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(diphenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165112-62-9 CAPLUS


CN 2,4-Dioxo-7,10-diazatridecan-13-oic acid, 11-[[[2,6-dichlorobenzoyl)oxy]acetyl]-8-methyl-5-(1-methylethyl)-3,6,9-trioxo-1-phenyl- (9CI) (CA INDEX NAME)

09/284,424



RN 165112-85-6 CAPLUS
CN Glycinamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N2-(2,3-dihydro-1H-inden-
2-yl)-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 29 OF 36 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1995:388930 CAPLUS
DOCUMENT NUMBER: 122:281409
TITLE: Structural and stereochemical requirements of
time-dependent inactivators of the
interleukin-1.beta.
converting enzyme
AUTHOR(S): Prasad, C. V. C.; Prouty, Catherine P.; Hoyer,
Denton;
Ross, Tina M.; Salvino, Joseph M.; Awad, Mohamad;
Graybill, Todd L.; Schmidt, Stanley J.; Osifo, I.
Kelly; et al.
CORPORATE SOURCE: Department of Medicinal Chemistry, Sterling Winthrop
Pharmaceuticals Research Division, Collegeville, PA,
19426, USA


SOURCE: Bioorg. Med. Chem. Lett. (1995), 5(4), 315-18
 CODEN: BMCLE8; ISSN: 0960-894X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 151594-01-3 153088-74-5 162852-51-9
 162852-52-0 162852-53-1 162852-54-2
 162852-55-3 162852-56-4 162852-57-5
 162990-39-8
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (structural and stereochem. requirements of time-dependent
 inactivators
 of interleukin-1.β. converting enzyme)
 RN 151594-01-3 CAPLUS
 CN L-Alaninamide,
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
 [(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153088-74-5 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-3-methyl-1-oxo-2-
 [[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 162852-51-9 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[3-(1H-imidazol-4-yl)-2-
 [(methoxycarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester,
 [S-(R*,R*)]-

09/284,424

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162852-52-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-,

4-carboxy-3-[[[(methoxycarbonyl)amino]acetyl]

amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-53-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162852-54-2 CAPLUS

09/284,424

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxo-3-(2-thienyl)propyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-55-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-56-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-2-oxo-3-[[1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]butyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



09/284,424


RN 162852-57-5 CAPLUS
CN L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 162990-39-8 CAPLUS
CN D-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 30 OF 36 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1995:326801 CAPLUS
DOCUMENT NUMBER: 122:103682
TITLE: Inhibition of mature IL-1 β production in murine macrophages and a murine model of inflammation by WIN 67694, an inhibitor of IL-1 β converting enzyme
AUTHOR(S): Miller, Bruce E.; Krasney, Philip A.; Gauvin, Donna M.; Holbrook, Kim B.; Koonz, David J.; Abruzzese, Ronald V.; Miller, Robert E.; Pagani, Karen A.;
Dolle, Roland E.; et al.
CORPORATE SOURCE: Research Division, Sterling Winthrop Pharmaceuticals, Collegeville, PA, 19426, USA
SOURCE: J. Immunol. (1995), 154(3), 1331-8
CODEN: JOIMA3; ISSN: 0022-1767

09/284,424

DOCUMENT TYPE: Journal
LANGUAGE: English

IT 151594-01-3

RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)

(inhibition of mature IL-1.beta. prodn. in murine macrophages and an
inflammation model by IL-1.beta. converting enzyme inhibitor WIN


67694)

RN 151594-01-3 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 31 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:297974 CAPLUS

DOCUMENT NUMBER: 122:45691

TITLE: Aspartyl .alpha.-((Diphenylphosphinyl)oxy)methyl
Ketones as Novel Inhibitors of Interleukin-1.beta.
Converting Enzyme. Utility of the Diphenylphosphinic
Acid Leaving Group for the Inhibition of Cysteine
Proteases

AUTHOR(S): Dolle, Roland E.; Singh, Jasbir; Whipple, David;
Osifo, I. Kelly; Speier, Gary; Graybill, Todd L.;
Gregory, Jill S.; Harris, Alex L.; Helaszek, Carla

T.;

et al.
CORPORATE SOURCE: Department of Medicinal Chemistry, Sterling Winthrop
Pharmaceuticals Research Division, Collegeville, PA,
19426, USA

SOURCE: J. Med. Chem. (1995), 38(2), 220-2
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 153088-74-5

RL: BAC (Biological activity or effector, except adverse); PRP
(Properties); BIOL (Biological study)


(aspartyl ((diphenylphosphinyl)oxy)methyl ketones as novel inhibitors
of interleukin-1.beta. converting enzyme in relation to utility of
diphenylphosphinic acid leaving group for inhibition of cysteine
proteases)

RN 153088-74-5 CAPLUS

09/284,424


CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-3-methyl-1-oxo-2-
[[[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 32 OF 36 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1995:66276 CAPLUS
DOCUMENT NUMBER: 122:122694
TITLE: Activated ketones as potent reversible inhibitors of
interleukin-1.beta. converting enzyme
AUTHOR(S): Mjalli, Adnan M. M.; Chapman, Kevin T.; MacCoss,
Malcolm; Thornberry, Nancy A.; Peterson, Erin P.
CORPORATE SOURCE: Dep. Med. Chem. Res., Merck Res. Lab., Rahway, NJ,
07065, USA
SOURCE: Bioorg. Med. Chem. Lett. (1994), 4(16), 1965-8
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 160837-67-2
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(activated ketones as potent reversible inhibitors of
interleukin-1.beta. converting enzyme)
RN 160837-67-2 CAPLUS
CN L-Alaninamide,
N-(1-oxo-3-phenylpropyl)-L-valyl-N-[1-(carboxymethyl)-2-oxo-
3-(1-oxo-3-phenylpropoxy)propyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 33 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1994:264340 CAPLUS

DOCUMENT NUMBER: 120:264340

TITLE: Inactivation of Interleukin-1.β. Converting Enzyme
by Peptide (Acyloxy)methyl KetonesAUTHOR(S): Thornberry, Nancy A.; Peterson, Erin P.; Zhao, Justin
J.; Howard, Andrew D.; Griffin, Patrick R.; Chapman,
Kevin T.CORPORATE SOURCE: Department of Enzymology Medicinal Chemical Research,
Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: Biochemistry (1994), 33(13), 3934-40

CODEN: BICHAW; ISSN: 0006-2960

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 151272-16-1P 151272-17-2P 154674-81-4P

154674-82-5P 154674-84-7P 154674-86-9P

154719-25-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of and human interleukin-1.β.-converting enzyme inhibition
by, structure in relation to)

RN 151272-16-1 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-[[2,6-
bis(trifluoromethyl)benzoyloxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 151272-17-2 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-(benzoyloxy)-1-
(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/284,424

RN 154674-81-4 CAPLUS
CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-1-(carboxymethyl)-3-
[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OH

RN 154674-82-5 CAPLUS
CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-3-[[2,6-
bis(trifluoromethyl)benzoyl]oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OH

—OH


RN 154674-84-7 CAPLUS
 CN L-Alaninamide,
 N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
 3-[(2,6-dihydroxybenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154674-86-9 CAPLUS
 CN L-Alaninamide,
 N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
 3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154719-25-2 CAPLUS
 CN L-Lysinamide, N-acetyl-L-tyrosyl-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-
 dimethylbenzoyl)oxy]-2-oxopropyl]-N6-[5-(hexahydro-2-oxo-1H-thieno[3,4-
 d]imidazol-4-yl)-1-oxopentyl]-, [3aS-[3a.alpha.,4.beta.(R*),6a.alpha.]]-
 (9CI) (CA INDEX NAME)




DOCUMENT NUMBER: 120:152995
 TITLE: P1 Aspartate-Based Peptide .alpha.-((2,6-Dichlorobenzoyl)oxy)methyl Ketones as Potent Time-Dependent Inhibitors of Interleukin-1.beta.-Converting Enzyme
 AUTHOR(S): Dolle, Roland E.; Hoyer, Denton; Prasad, C. V. C.; Schmidt, Stanley J.; Helaszek, Carla T.; Miller, Robert E.; Ator, Mark A.
 CORPORATE SOURCE: Department of Medicinal Chemistry and Enzymology and Receptor Biochemistry1, Collegeville, PA, 19426, USA
 SOURCE: J. Med. Chem. (1994), 37(5), 563-4
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 151594-01-3P 153088-74-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of and interleukin-1.beta.-converting enzyme inhibition by, structure in relation to)
 RN 151594-01-3 CAPLUS
 CN L-Alaninamide,
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153088-74-5 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-3-methyl-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 35 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1994:77637 CAPLUS
 DOCUMENT NUMBER: 120:77637
 TITLE: Preparation of peptides useful for inhibiting
 IL-1.beta. release
 INVENTOR(S): Heng, Richard; Payne, Trevor Glyn; Revesz, Laszlo;
 Weidmann, Beat
 PATENT ASSIGNEE(S): Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.,
 Austria; Sandoz-Patent-G.m.b.H.; Sandoz Ltd.
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9309135	A1	19930513	WO 1992-EP2472	19921029
W: AU, CA, CS, FI, HU, JP, KR, NO, PL, RO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9228852	A1	19930607	AU 1992-28852	19921029
EP 611375	A1	19940824	EP 1992-922580	19921029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
JP 07500828	T2	19950126	JP 1992-508146	19921029
HU 68200	A2	19950529	HU 1994-1303	19921029
ZA 9208511	A	19940504	ZA 1992-8511	19921104
CN 1094730	A	19941109	CN 1993-105500	19930503
NO 9401629	A	19940704	NO 1994-1629	19940503
FI 9402061	A	19940504	FI 1994-2061	19940504
PRIORITY APPLN. INFO.:			GB 1991-23326	19911104
			WO 1992-EP2472	19921029
OTHER SOURCE(S): MARPAT 120:77637				
IT 151544-27-3P 151544-31-9P 151544-35-3P				
151544-36-4P 151544-42-2P 151594-01-3P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(prepn. of, as inhibitor of IL-1.beta. release)				
RN	151544-27-3 CAPLUS			
CN	L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI)			
	(CA INDEX NAME)			


09/284,424



RN 151544-31-9 CAPLUS

CN L-Histidinamide,


N-[(phenylmethoxy)carbonyl]-D-valyl-N-[1-(carboxymethyl)-
3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)



RN 151544-35-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[3-(1H-imidazol-4-yl)-1-oxo-2-
[[[(phenylmethoxy)carbonyl]amino]propyl]amino]-2-oxobutyl ester,
[S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



09/284,424


RN 151544-36-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[3-(1H-imidazol-4-yl)-1-oxo-2-[[3-(phenylmethoxy)benzoyl]amino]propyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 151544-42-2 CAPLUS
CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151594-01-3 CAPLUS
CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/284,424



L4 ANSWER 36 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1993:641381 CAPLUS

DOCUMENT NUMBER: 119:241381

TITLE: Peptidyl derivatives as inhibitors of interleukin-1.β. converting enzyme

INVENTOR(S): Chapman, Kevin T.; Maccoss, Malcolm; Mjalli, Adnan

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9316710	A1	19930902	WO 1993-US1321	19930212
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9336668	A1	19930913	AU 1993-36668	19930212
EP 627926	A1	19941214	EP 1993-905939	19930212
EP 627926	B1	19980805		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07504194	T2	19950511	JP 1993-514912	19930212
AT 169224	E	19980815	AT 1993-905939	19930212
ES 2118940	T3	19981001	ES 1993-905939	19930212
US 5430128	A	19950704	US 1994-342991	19941121
PRIORITY APPLN. INFO.:				
			US 1992-839590	19920221
			WO 1993-US1321	19930212
			US 1993-67412	19930525

OTHER SOURCE(S): MARPAT 119:241381

IT 151272-16-1P 151272-17-2P 151272-18-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of and interleukin-1-mediated diseases treatment with, interleukin-1.β. converting enzyme inhibition in relation to)

RN 151272-16-1 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-[[2,6-bis(trifluoromethyl)benzoyl]oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 151272-17-2 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-(benzoyloxy)-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 151272-18-3 CAPLUS

CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[1-(carboxymethyl)-2-oxo-3-[(pentafluorobenzoyl)oxy]propyl]-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



09/284,424

PAGE 1-B

